Rhumbline Advisers Sage Therapeutics, Inc. Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

A detailed history of Rhumbline Advisers transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 77,429 shares of SAGE stock, worth $822,295. This represents 0.0% of its overall portfolio holdings.

Number of Shares

77,429

Previous 75,683 2.31%

Holding current value

$822,295

Previous $1.64 Million 11.52%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$18.62 - $26.95 $32,510 - $47,054	1,746 Added 2.31%	77,429 $1.45 Million
Q4 2023 Feb 08, 2024	SELL	$17.1 - $22.26 $6,173 - $8,035	-361 Reduced 0.47%	75,683 $1.64 Million
Q3 2023 Nov 09, 2023	BUY	$16.75 - $48.98 $13,132 - $38,400	784 Added 1.04%	76,044 $1.56 Million
Q2 2023 Aug 08, 2023	SELL	$40.65 - $59.54 $432,231 - $633,088	-10,633 Reduced 12.38%	75,260 $3.54 Million
Q1 2023 May 11, 2023	BUY	$37.27 - $46.57 $69,284 - $86,573	1,859 Added 2.21%	85,893 $3.6 Million

Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $46,368 - $62,798	1,440 Added 1.74%	84,034 $3.21 Million
Q3 2022 Nov 10, 2022	BUY	$32.28 - $43.27 $174,473 - $233,874	5,405 Added 7.0%	82,594 $3.23 Million
Q2 2022 Aug 11, 2022	BUY	$27.52 - $37.99 $959,484 - $1.32 Million	34,865 Added 82.38%	77,189 $2.49 Million
Q1 2022 May 12, 2022	SELL	$30.71 - $45.71 $169,642 - $252,502	-5,524 Reduced 11.54%	42,324 $1.4 Million
Q4 2021 Feb 10, 2022	BUY	$37.06 - $47.11 $3,409 - $4,334	92 Added 0.19%	47,848 $2.04 Million
Q3 2021 Nov 12, 2021	SELL	$40.26 - $57.37 $172,514 - $245,830	-4,285 Reduced 8.23%	47,756 $2.12 Million
Q2 2021 Aug 05, 2021	SELL	$54.88 - $79.29 $186,811 - $269,903	-3,404 Reduced 6.14%	52,041 $2.96 Million
Q1 2021 May 06, 2021	SELL	$70.65 - $96.76 $150,484 - $206,098	-2,130 Reduced 3.7%	55,445 $4.15 Million
Q4 2020 Feb 10, 2021	BUY	$58.41 - $89.06 $58,994 - $89,950	1,010 Added 1.79%	57,575 $4.98 Million
Q3 2020 Nov 12, 2020	SELL	$41.13 - $62.45 $41,541 - $63,074	-1,010 Reduced 1.75%	56,565 $3.46 Million
Q2 2020 Aug 13, 2020	BUY	$25.95 - $43.15 $164,808 - $274,045	6,351 Added 12.4%	57,575 $2.39 Million
Q1 2020 May 06, 2020	SELL	$26.15 - $77.24 $18,723 - $55,303	-716 Reduced 1.38%	51,224 $1.47 Million
Q4 2019 Feb 05, 2020	BUY	$60.18 - $154.77 $70,530 - $181,390	1,172 Added 2.31%	51,940 $3.75 Million
Q3 2019 Oct 23, 2019	SELL	$140.29 - $189.96 $34,230 - $46,350	-244 Reduced 0.48%	50,768 $7.12 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $367,474 - $426,233	2,328 Added 4.78%	51,012 $9.34 Million
Q1 2019 May 01, 2019	BUY	$89.33 - $163.65 $158,739 - $290,806	1,777 Added 3.79%	48,684 $7.74 Million
Q4 2018 Jan 31, 2019	SELL	$81.94 - $139.71 $117,174 - $199,785	-1,430 Reduced 2.96%	46,907 $4.49 Million
Q3 2018 Nov 07, 2018	SELL	$138.11 - $169.04 $127,751 - $156,362	-925 Reduced 1.88%	48,337 $6.83 Million
Q2 2018 Aug 06, 2018	BUY	$140.36 - $175.76 $1.17 Million - $1.46 Million	8,307 Added 20.28%	49,262 $7.71 Million
Q1 2018 May 02, 2018	BUY	$152.15 - $192.33 $369,572 - $467,169	2,429 Added 6.3%	40,955 $6.6 Million
Q4 2017 Feb 09, 2018	SELL	$60.72 - $167.34 $233,468 - $643,422	-3,845 Reduced 9.07%	38,526 $6.35 Million
Q3 2017 Nov 06, 2017	BUY	$61.4 - $88.52 $2.6 Million - $3.75 Million	42,371	42,371 $2.64 Million

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $631M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Sage Therapeutics, Inc. Transaction History